Patents Assigned to Pfizer Health AB
-
Patent number: 9801995Abstract: The invention relates to a cover for housing a syringe, an assembly comprising such cover, a pen-injector comprising such assembly and a method for forming a pen-injector.Type: GrantFiled: March 14, 2012Date of Patent: October 31, 2017Assignee: Pfizer Health ABInventors: Francesco DeRosa, Torbjorn Lindwall, Anna Sahlin
-
Patent number: 8535274Abstract: The injection device comprises a housing designed or suitable for manual gripping, a container for a preparation attached/enclosed in the housing, an outlet for the preparation exposed with respect to the housing and a mechanism arranged for moving the preparation at least from the container through the outlet. The system comprises a set of at least two elements having different properties in at least one respect. The elements are designed for mechanical attachment to one and the same area part of the housing, one at the time. The method includes the steps of providing at least two elements having different properties in at least one respect, the elements being designed for mechanical attachment to one and the same area part of the housing, one at the time, selecting one element from the set, and attaching mechanically the selected element to said area part of the housing.Type: GrantFiled: April 22, 2008Date of Patent: September 17, 2013Assignee: Pfizer Health ABInventors: Birger Hjertman, Hans Himbert, Bohdan Pavlu, Kerstin Genetay
-
Publication number: 20090130189Abstract: Devices for transdermal administration of nicotine, which provide for basic as well as additional user activatable administration of nicotine, as well as use of such devices.Type: ApplicationFiled: March 10, 2005Publication date: May 21, 2009Applicant: PFIZER HEALTH ABInventors: Fredrik Nicklasson, Kristina Thyresson, Katarina Lindell
-
Patent number: 7396347Abstract: Injector device, and method for its operation, for containers of syringe type, comprising a barrel of axially roughly constant cross-section, a front opening and at least one movable wall inserted in the barrel for displacement of a container content, the injector comprising a) a housing or housing part arranged to receive the container at least axially stationary, b) an integral or composite piston rod arrangement operable to displace the container movable wall at least in the forward direction and c) a track system for controlling or sequencing the piston rod movements, the track system comprising at least one cooperating track and follower, the cooperating track and follower being arranged stationary with respect to the housing and the piston rod respectively, or vice versa, and in cooperation allowing at least one forward for the piston rod. The track system comprises arrangements initiation, dose setting and expulsion of container content.Type: GrantFiled: March 26, 2003Date of Patent: July 8, 2008Assignee: Pfizer Health ABInventors: Birger Hjertman, Rudolf Cseke
-
Publication number: 20070037861Abstract: The application relates to the treatment of conditions and diseases for which growth hormone is a desirable method of treatment, using free fatty acid regulators in combination with growth hormone. In particular, the present invention discloses an enhanced method of treatment of growth disorders as well as methods to prevent and/or reduce adverse consequences of growth hormone treatment.Type: ApplicationFiled: September 14, 2004Publication date: February 15, 2007Applicant: PFIZER HEALTH ABInventors: Wayne Cutfield, Paul Hofman, Mark Vickers
-
Patent number: 7008637Abstract: The present invention is drawn to set of formulations of at least one compound selected from tolterodine, salts thereof, prodrugs thereof and/or metabolites thereof, wherein in the set of formulations contains at least one device for transdermal administration and at least one formulation for oral, sublingual, buccal, nasal, pulmonary, rectal and/or other transmucosal administration, in order to achieve an effect against overactive bladder and/or symptoms associated with this condition. The present invention is further drawn to methods of treating an overactive bladder with the formulations.Type: GrantFiled: November 22, 2002Date of Patent: March 7, 2006Assignee: Pfizer Health ABInventors: Lene Orup Jacobsen, Bo Kreilgard, Ulla Hoeck, Helle Kristensen
-
Patent number: 6790496Abstract: A material for packaging a nicotine product comprising a polymer based on dimethyl-2,6-naphthalene dicarboxylic or 2,6-naphthalene dicarboxylic acid monomers, such as polyethylene naphtalate (PEN) or polytrimethylene naphtalate (PTN), or a liquid crystal polymer (LPC). The material may be laminated to another polymer or to metal foil.Type: GrantFiled: October 17, 2001Date of Patent: September 14, 2004Assignee: Pfizer Health ABInventors: Gustav Levander, Anders H. F. Karlsson, Ingemar Hildingsson
-
Patent number: RE39667Abstract: The invention relates to 3,3-diphenylpropylamines of formula (I), wherein R1 signifies hydrogen or methyl, R2 and R3 independently signify hydrogen, methyl, methoxy, hydroxy, carbamoyl, sulphamoyl or halogen, and X represents a tertiary amino group of formula (II), wherein R4 and R5 signify non-aromatic hydrocarbyl groups, which may be the same or different and which together contain at least three carbon atoms, and wherein R4 and R5 may form a ring together with the amine nitrogen, their salts with physiologically acceptable acids and, when the compounds can be in the form of optical isomers, the racemic mixture and the individual enantiomers.Type: GrantFiled: November 5, 1993Date of Patent: May 29, 2007Assignee: Pfizer Health ABInventors: Rolf A. Johansson, Pinchas Moses, Lisbeth Nilvebrant, Bengt A. Sparf
-
Patent number: RE40851Abstract: The invention relates to 3,3-diphenylpropylamines of formula (I), wherein R1 signifies hydrogen or methyl, R2 and R3 independently signify hydrogen, methyl, methoxy, hydroxy, carbamoyl, sulphamoyl or halogen, and X represents a tertiary amino group of formula (II), wherein R4 and R5 signify non-aromatic hydrocarbyl groups, which may be the same or different and which together contain at least three carbon atoms, and wherein R4 and R5 may form a ring together with the amine nitrogen, their salts with physiologically acceptable acids and, when the compounds can be in the form of optical isomers, the racemic mixture and the individual enantiomers.Type: GrantFiled: November 5, 1993Date of Patent: July 14, 2009Assignee: Pfizer Health ABInventors: Rolf A. Johansson, Pinchas Moses, Lisbeth Nilvebrant, Bengt A. Sparf